Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when ...
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...